New study pits Clot-Removal devices against drugs for dangerous lung clots

NCT ID NCT06453876

Recruiting now Disease control Sponsor: Jesper Kjaergaard Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This phase 3 trial will test three ways to treat intermediate high-risk pulmonary embolism (a serious blood clot in the lungs). The study compares two catheter-based procedures (mechanical clot removal or low-dose clot-busting drug) with standard blood-thinning heparin. About 210 adults with recent symptoms will be enrolled. The goal is to see which method reduces clot burden most effectively within 48-96 hours.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Heparin, Alteplase, and catheter-based devices (AlphaVAC, FlowTriever, EKOS)
What this could lead to: If successful, this trial could identify the best approach to quickly reduce blood clots in the lungs, potentially improving recovery and reducing complications for people with serious pulmonary embolism.
What could go wrong: This is a phase 3 trial, but results may not apply to all patients. Bleeding risks exist with all treatments, and the study is relatively small (210 participants).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY EMBOLISM

Contacts and locations

Locations

Copenhagen University Hospital Rigshospitalet
RECRUITING

Copenhagen, DK2100, Denmark
Odense University Hospital
NOT_YET_RECRUITING

Odense, 5000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.